PharmAust has hit a major milestone, signing a landmark deal with US pharmaceutical giant Elanco to develop the company’s promising anti-cancer drug “Monepantel”. The deal will see Elanco supply PharmAust with high-grade Monepantel for use in clinical trials in dogs with cancer and in return Pharmaust will grant Elenco an option to negotiate a deal to take Pharmaust's IP to the global market.
19/04/2018 - 04:38
PharmAust inks anti-cancer deal with giant Pharma
By Matt Birney
19/04/2018 - 04:38
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX